Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $93.00. The company’s shares closed yesterday at $26.62.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rahimi covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Soleno Therapeutics, and Crinetics Pharmaceuticals. According to TipRanks, Rahimi has an average return of 13.1% and a 41.74% success rate on recommended stocks.
Currently, the analyst consensus on Structure Therapeutics, Inc. Sponsored ADR is a Strong Buy with an average price target of $71.36, representing a 168.07% upside. In a report released on September 23, H.C. Wainwright also maintained a Buy rating on the stock with a $60.00 price target.
GPCR market cap is currently $1.53B and has a P/E ratio of -8.51.
Read More on GPCR:
Disclaimer & DisclosureReport an Issue
- Buy Rating for Structure Therapeutics: Aleniglipron’s Market Potential and Acquisition Appeal
- Promising Market Potential for Structure Therapeutics: Buy Rating Backed by Superior Trial Results and Market Opportunities
- Optimistic Buy Rating for Structure Therapeutics Driven by Aleniglipron’s Potential in Obesity and T2D Markets
- Structure Therapeutics price target lowered to $90 from $92 at Guggenheim
- Structure Therapeutics price target raised to $75 from $60 at H.C. Wainwright
/AI%20(artificial%20intelligence)/AI%20engineer%20working%20on%20laptop%20by%20ART%20STOCK%20CREATIVE%20via%20Shutterstock.jpg)
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)